[Analysis of tumor lysis syndrome in 380 cases of acute leukemia].
作者信息
Zhang Qi, Liu Kai-Qi, Liu Bing-Cheng, Zhou Chun-Lin, Li Wei, Lin Dong, Wang Ying, Mi Ying-Chang, Wang Jian-Xiang
机构信息
Diagnostic and Therapeutic Center of Leukemia, Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Diagnostic and Therapeutic Center of Leukemia, Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. E-mail:
出版信息
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Feb;23(1):61-4. doi: 10.7534/j.issn.1009-2137.2015.01.012.
OBJECTIVE
This studay was aimed to explore the incidence and risk factors of tumor lysis syndrome (TLS) in patients with acute leukemia.
METHODS
A tatol of 380 patients who were newly diagnosed as acute leukemia and received combination chemotherapy were retrospectively analyzed. The TLS was diagnosed according to criteria of Cario and Bioshop, the risk factors were evaluated on basis of examination results.
RESULTS
The tumor lysis syndrome occurred in 20.8% (79/380) of patients, out of them the clinical TLS was 0.5% (2/380), laboratorial TLS was 20.3% (77/380). The unvariate analysis showed that male, high WBC count, hepatomegaly, splenomegaly, lympha-denoctasis, elevated AST, high creatinine, high uric acid level, high serum lactate dehydrogenase (LDH) level, or renal insufficiency were independent risk factors for TLS.
CONCLUSION
The TLS is a clinically common complication in patients with leukemia, especially during induction chemotherapy, therefore, for AL patients with high risk factors the TLS should be closely monitored, prevented and given better therapy.
Zotero 插件